Drug development company BiVictriX Therapeutics PLC (LON:BVX) is planning to float on AIM by the end of the month as it looks to develop its next-generation cancer therapy platform.
The Macclesfield-based was founded by clinical immunologist Tiffany Thorn, former head of therapeutic development at ADC Biotechnology Ltd, who invented the Bi-Cygni technology around which the company is based.
Bi-Cygni used antibody drug conjugates, an existing class of potent biological drugs, as a potential treatment of various cancers that is designed to enable higher dosing and more aggressive cancer eradication without causing harmful side-effects.
Thorn has identified a unique, cancer-restricted antigen fingerprint that is not present in healthy cells and can be exploited to produce cancer-selective therapeutics.
These treatments aim to “attack the cancer, not the patient”, as the company’s website says, with only cancer cells targets and healthy cells left alone.
The lead drug programme is targeting a treatment for acute myeloid leukaemia, an aggressive form of blood cancer.
BiVictriX’s work to date has demonstrated its ADCs’ superior potency and tumour selectivity compared to conventional ADCs.
At Thorn’s side in the boardroom is non-executive chairman Iain Ross, a veteran of listed drug developers including Silence Therapeutics, Allergy Therapeutics, e-Therapeutics and others.
Since being founded in 2016 the company has secured GBP2.3mln of investment, with its AIM funding plans still being finalised.